Aadi Bioscience Inc
:ARPO
Regulatory, Earnings Announcements
Aerpio Announces Statistically Significant Topline Results From Razuprotafib Glaucoma Phase 2 Trial
Published: 12/11/2020 22:06 GMT
(ARPO) - Aerpio Announces Statistically Significant Topline Results From Razuprotafib Glaucoma Phase 2 Trial.
Aerpio Pharmaceuticals Inc - Primary Endpoint Achieved With Twice-daily Dose Group at 28 Day Time Point Versus Latanoprost Control Group.
Aerpio Pharmaceuticals Inc - Patient Enrollment and Dosing Continues in Both Covid-19 Clinical Trials.
Aerpio - 2 Ongoing Clinical Trials of Razuprotafib in Covid-19 Patients Continue, Remain on Track to Provide Additional Updates in H1 2021.
Aerpio Pharmaceuticals Inc - Primary Endpoint Achieved With Twice-daily Dose Group at 28 Day Time Point Versus Latanoprost Control Group.
Aerpio Pharmaceuticals Inc - Patient Enrollment and Dosing Continues in Both Covid-19 Clinical Trials.
Aerpio - 2 Ongoing Clinical Trials of Razuprotafib in Covid-19 Patients Continue, Remain on Track to Provide Additional Updates in H1 2021.